Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (June 2017)
26 slides from Ani Pharmaceuticals's investor presentation, Jun 6, 2017
Slide 1: Corporate Presentation June 2017
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation June 2017
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, stat
Slide 3: Mission and Strategy
3 3 Mission and Strategy ANI Pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing , manufacturing and marketing high quality branded and generic prescription pharmaceuticals. Our dedicated team of R&D, business development, manu
Slide 4: Senior Management Team
4 Senior Management Team 4 With ANI Yrs Industry Since Experience Previous Affiliation Arthur Przybyl President and CEO 2009 25+ Akorn Stephen Carey VP, Finance and CFO 2016 20+ Par Pharmaceutical Robert Schrepfer SVP, Business Development and 2013 15 Healthcare Value Capital Specialty Sales James M
Slide 5: Financial Highlights - 1Q 2017
5 Financial Highlights - 1Q 2017 Strong first quarter performance coming off of a record year of results in 2016: 27 commercial product families as of March 31, 2017, up from 16 at the beginning of 2016 Quarterly net revenues increased 78% from prior year Quarterly adjusted non - GAAP EBITDA increas
Slide 6: Financial Highlights - 1Q Net Revenues
6 Financial Highlights - 1Q Net Revenues Generic sales gains driven by eight products launched during 2016 (detailed on slide 11) Brand sales reflect April 2016 launch of Inderal ® LA and the late February 2017 introduction of InnoPran XL ® and Inderal ® XL Contract manufacturing reflects timing and
Slide 7: 2017 Guidance
7 2017 Guidance Forecast results projected to be driven by: Annualization and continued operational focus on maximizing 2016 launches Expansion of our brand revenues with the addition of InnoPran XL ® and Inderal ® XL Execution of 2017 generic product launches Increasing the investment behind our Co
Slide 8: Historical 5-Year Revenue and Adjusted EBITDA Growth
8 $- $20 $40 $60 $80 $100 $120 $140 2011 2012 2013 2014 2015 2016 Revenues EBITDA Historical 5 - Year Revenue and Adjusted EBITDA Growth 8 $s in millions
Slide 9: Sales and Marketing Overview
9 9 Sales and Marketing Overview
Slide 10: Generic Rx Product Portfolio: 2016 & 2017 Product Introductions
10 Generic Rx Product Portfolio 2016 & 2017 Product Introductions Erythromycin Ethylsuccinate Fenofibrate Capsules (AG) HC Cream, for rectal use Indapamide (April 2017) Lithium Carbonate ER (AG) Mesalamine Enema (AG) Nilutamide Tablets Oxycodone Capsules Pindolol (May 2017) Propranolol ER Capsules (
Slide 11: Generic Rx Product Portfolio: Foundational Products
11 Generic Rx Product Portfolio Foundational Products (launched prior to 2016) 11 (AG) = Authorized Generic EE/MT Tablets Etodolac Capsules Flecainide Tablets Fluvoxamine Maleate Tablets (AG) HC Enema (AG) Methazolamide Tablets Metoclopramide Solution Nimodipine Capsules Opium Tincture Oxycodone Ora
Slide 12: Brand Rx Product Portfolio
12 Brand Rx Product Portfolio Lithobid ® Tablets Bipolar Disorder Vancocin ® Capsules C. difficile - Associated Diarrhea Cortenema ® U lcerative Colitis Reglan ® Tablets Gastroesophageal Reflux Inderal ® LA Capsules Hypertension ▪ $26.4 million of full year 2016 and $8.0M of first quarter 2017 brand
Slide 13: Brand Rx: InnoPran XL and Inderal XL
13 Brand Rx InnoPran XL ® and Inderal ® XL 13 Two additional hypertension brands acquired in first quarter 2017: Purchased on February 23, 2017, for approximately $51 million Generated combined sales of $23.3 million in 2016 according to IMS Health data (gross sales basis) Second quarter of 2017 wil
Slide 14: Contract Manufacturing and Other
14 Contract Manufacturing and Other 14 Contract manufacturing ▪ $5.5 million of full year 2016 and $1.8M of first quarter 2017 net revenues ▪ Four customers – Seven products and seventeen SKUs – Contract manufacturing and contract packaging Contract services and other ▪ $1.4 million of full year 201
Slide 15: Business and Product Development Overview
15 15 Business and Product Development Overview
Slide 16: Business Development Activity - Generics
16 Business Development Activity - Generics 16 P $0.0 Acquisition of US Distr Rights Nimodipine & Omega Private P P $10.0 IDT Partnership (18 previously approved ANDAs) P $1.0 P P Rowasa AG (Partnership with Meda) US Distr Rights Private P Lipofen AG & 1% and 2.5% HC Cream US Distr Rights Private US
Slide 17: Business Development Activity - Brands
17 Business Development Activity - Brands 17 (lithium carbonate tablets) $11.0 Vancocin® $209.0Total P Private (vancomycin hydrochloride capsules) Acquisition P P STRUCTURE SOURCE STRATEGY ANI MANUF APPROVED COST ($M) $60.0 Inderal® LA (propranolol ER capsules) Private P P B r a n d s Acquisition Pr
Slide 18: Product Development Pipeline
18 18 Product Development Pipeline ANI Pipeline ▪ 77 products in development, total combined current market: $3.8 billion (1) ▪ 53 products were acquired and of those, ANI believes 46 can be commercialized based on either a CBE - 30 or PAS Corticotropin Re - commercialization Update ▪ Identified, in
Slide 19: Manufacturing Overview
19 19 Manufacturing Overview
Slide 20: Manufacturing – Main Street Facility
20 20 Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 sq. ft. of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of laboratory
Slide 21: Manufacturing – IDC Road Facility
21 21 Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing, packaging , and warehouse facilities ▪ 100 nano - gram per eight - hour
Slide 22: Summary
22 Summary ANI is an integrated specialty generic pharmaceutical company with: ▪ Profitable base business generating organic growth ▪ Strong capital position ▪ Experienced management team ▪ US - based manufacturing assets and expertise ▪ 2017 Annual guidance (1) – Net revenues of $181 million to $19
Slide 23: Appendix A
23 23 Appendix A
Slide 24: U.S. GAAP Reconciliations
24 U.S. GAAP Reconciliations 24 2017 2016 Net Income 1,152$ 1,346$ Add back Interest expense, net 2,932 2,782 Other income/(expense), net 18 (2) Provision for income taxes 523 1,540 Depreciation and amortization 6,706 4,609 Add back Stock-based compensation 1,386 1,105 Excess of fair value over cost
Slide 25: U.S. GAAP Reconciliations
25 U.S. GAAP Reconciliations 25 2017 2016 Net Income 1,152$ 1,346$ Add back Non-cash interest expense 1,792 1,725 Depreciation and amortization expense 6,706 4,609 Stock-based compensation 1,386 1,105 Excess of fair value over cost of acquired inventory 1,535 - Expenses related to transaction not co
Slide 26: U.S. GAAP Reconciliations
26 U.S. GAAP Reconciliations 26 Non - GAAP Financial Measures included in 2017 Guidance The Company's fiscal 2017 guidance for adjusted non - GAAP EBITDA and adjusted non - GAAP diluted earnings per share is not reconciled to the most comparable GAAP measure. This is due to the inherent difficulty o
ANI Pharmaceuticals — Investor Presentation (June 2017) on 6ix